DGAP-News: Neovacs S.A. / Key word(s): Study NEOVACS OBTAINS SOUTH KOREA HEALTH AUTHORITY APPROVAL FOR IND APPLICATION WITH INFα KINOID IN LUPUS 14.04.2016 / 09:45 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- PRESS RELEASE NEOVACS OBTAINS SOUTH KOREA HEALTH AUTHORITY APPROVAL FOR IND APPLICATION WITH INFα KINOID IN LUPUS Paris, April 14th, 2016 - NEOVACS (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced that South Korea health authority approved Neovacs's Investigational New Drug application for IFNα Kinoid in phase IIb development in Lupus. Miguel Sieler, CEO of NEOVACS commented about this trial, now including South Korea: "The examination of our trial has been particularly detailed and has therefore taken into consideration the innovative character of our technology in the frame of the development of a new therapeutic approach for a rare disease. Indeed the Korean health authorities were very demanding and wanted to analyze and understand clearly the mechanism of action and the preclinical and clinical data obtained so far as well as the different steps of production. This result is now an expression of confidence which is encouraging for the future." Neovacs has indeed signed a licensing and partnering agreement with the Korean company Chong Kun Dan Pharmaceuticals (CKD), leader in South Korea in the field of immunosuppressive drugs. This country is the only one of the OECD where Lupus disease fulfills the requirements to obtain the Orphan disease status. Within this agreement Neovacs will file in a near future for "Orphan Drug Designation". In case of success of its Phase IIb trial the registration of the product and its launch in the Korean market could as consequence take place without a previous Phase III trial. Based on these elements having received this IND is of strategic importance for Neovacs and for CKD in order to launch IFNα Kinoid in the Korean market. This actually running Phase IIb trial, randomized, versus placebo and concerning 166 patients, covers more than 100 investigation centers in the world, including now 5 in South Korea. The results of this trial are expected for summer 2017. About Neovacs Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα Kinoid, an immunotherapy being developed for the indication of lupus. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. All information about Neovacs is available on the website: www.neovacs.fr Contacts Neovacs/ Charlène Masson +33 (0)1 53 10 93 00 cmasson@neovacs.com New Cap /Valentine Brouchot / Pierre Laurent +33 (0)1 44 71 94 94 neovacs@newcap.eu Investor Relations / Financial Communications Germany - MC Services Raimund Gabriel +49-89-21-02-28-30 raimund.gabriel@mc-services.eu Press / U.S. Inquiries - The Ruth Group Joanna Zimmerman / Joseph Green +1-646-536-7012 / 7013 jzimmerman@theruthgroup.com / jgreen@theruthgroup.com --------------------------------------------------------------------------- 14.04.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Neovacs S.A. 3-5, Impasse Reille 75014 Paris France Phone: +33 (0)1 53 10 93 00 Fax: +33 (0)1 53 10 93 03 E-mail: www.neovacs.fr Internet: info@neovacs.fr ISIN: FR0004032746 WKN: A1CVKR Listed: Regulated Unofficial Market in Stuttgart; Open Market in Frankfurt End of News DGAP News Service --------------------------------------------------------------------------- 454249 14.04.2016
DGAP-News: NEOVACS OBTAINS SOUTH KOREA HEALTH AUTHORITY
Top 10 Most Recent News Articles
Data Centers: More Power-Hungry Than Thirsty
Data Centers: Not Quite the Water Guzzlers We Feared Hold onto your hats, because the latest intel on data centers is changing the game, or at least forcing a closer look at what seems like a done deal. The big reveal? It's not the water, folks—it’s the juice. While everyone frets about water, electricity is the silent giant you’ve got to wrangle. Water vs....
Continue Reading
Fitness Career Platform's Big Ramp Up Sparks Buzz
ISSA Career Connect Gains Industry Recognition In a world where finding that first job post-certification can be as brutal as a spin class in August, ISSA Career Connect seems to be offering a bit of a lifeline. This platform, already making some serious noise in the fitness industry, has just snagged a place as a finalist for App of the Year at the 2026 Beyond Activ...
Continue Reading
Shorr Packaging's Sustainable Edge: EcoVadis Silver Triumph
EcoVadis Silver Badge: Shorr's Green Path Imagine this: Shorr Packaging strutting around with an EcoVadis Silver Badge pinned to its chest for not one, not two, but three years now. That's right, Shorr Packaging's been elbowing its way to the top tier with their sustainability drive, ranked in the 93rd percentile. For those not keeping score, that's top-notch, considering...
Continue Reading
Monotype's Inkwell: A Type Family with New Twists
Fresh Faces in the World of Type Out of the design trenches comes news that Monotype—the big cheese in type and tech—just rolled out four new styles in its well-liked Inkwell lineup. We're talking Inkwell Antique, Formal, Chancery, and Ornaments here. The idea? Give designers more room to play with tone. Let's chew on what this expansion means for folks rocking...
Continue Reading
WeFetch AI: A New Era in Barcode Precision
WeFetch AI: What's in a Name? Forget about GreenCore Solutions Corp. We're talking about WeFetch AI Corp. now. They've just changed their name, fulfilling a bureaucratic tick as of November 13, 2026. But it ain't just a name change; it's a whole new ballgame in AI-driven commerce. AI Shopping Without the Guesswork We've all been there. You think you've ordered that...
Continue Reading
Biointron's RushDATA™: Speeding Up Antibody Discovery
A New Chapter in Antibody Discovery Well, color me intrigued. Biointron, a name you'd recognize if you've got even a toe in the biotech pond, just threw a serious curveball into the antibody discovery game with RushDATA™—an AI- and machine learning-driven platform that's packing a punch. And it's not just about throwing tech buzzwords around; this thing clocks...
Continue Reading
Innovative Rotating Kitchen Organizer Up for Licensing
Dusting Off the Corners: A Fresh Spin on Kitchen Storage Just when you think there's nothing new under the sun when it comes to storing your kitchen gadgets, here comes an invention straight out of Billings, Montana. It's called The Rotating Kitchen Organizer, a nifty contraption that's all set to turn those dead corners into prime real estate. How many times have we...
Continue Reading
Greenberg Traurig's Brad Kaufman: A Mentor of Resolute Impact
A Milestone for Mentorship at Greenberg Traurig In the often cutthroat jungle of law, finding someone who actually gives a damn about you is as rare as finding a unicorn. Yet, there it is—Brad Kaufman, at the helm of Greenberg Traurig's professional development, proving that mentorship can be more than just a checkbox on a quarterly review. Award for Exceptional...
Continue Reading
Business Boom in 2026: Key Regions to Watch Now
Business Formations Break Records in 2026 I'm telling you, the entrepreneurial spirit is alive and kicking across the States this year. The latest numbers from Registered Agents Inc are clear as day: business is bustling. We're looking at 576,818 new business setups nationwide just in October 2026. That's outpacing the previous year by a whopping 8%. And if that doesn't...
Continue Reading
$10,000 Boost Fuels Nichols College's Archaeological Quest
Webster First's Generous Contribution It's not every day you see a credit union digging into history—literally. Webster First Federal Credit Union just dropped ten grand to fuel Nichols College's archaeological adventures. This isn't some trivial check to post on Instagram. No, we're talking about funding some serious ground-penetrating radar (GPR) gadgetry that's set...
Continue ReadingTop 5 Most Recently Viewed Articles
Diane Nussbaum Celebrated as Pinnacle Professional Leader
Diane Nussbaum Recognized for Excellence in Culinary Arts The Inner Circle proudly acknowledges Diane Nussbaum as a distinguished member in the ranks of Pinnacle Professionals. Her recent recognition underscores her invaluable contributions to the culinary world, especially in pastry arts and community engagement. Celebrating Achievements in Pastry Diane Nussbaum's career...
Continue Reading
Innovative Immunotherapy Approach Targeting Gastric Cancer Unveiled
New Insights into Immunotherapy for Gastric Cancer ImmPACT Bio, a pioneering clinical-stage biopharmaceutical company, is making significant strides in cancer treatment with its innovative IMPT-601 therapy. This groundbreaking approach focuses on Claudin18.2 and TGF-? bispecific CAR T-cell therapy, aiming to redefine how we tackle gastric cancer. Understanding IMPT-601...
Continue Reading
ASML Holding's P/E Ratio Analysis: Understanding its Value
Insights into ASML Holding's P/E Ratio In today's market, the share price of ASML Holding Inc. (NASDAQ: ASML) stands at $987.03, reflecting a rise of 2.12%. Although the stock experienced a decline of 6.22% over the last month, it has seen a significant surge of 46.89% over the past year. Investors might wonder about the stock's valuation, especially in light of the...
Continue Reading
Recent Insider Sales Raise Questions for Tetra Tech Stakeholders
Recent Insider Activity at Tetra Tech Kirsten M Volpi, a notable Board Member at Tetra Tech (NASDAQ: TTEK), recently made headlines with an insider sale. She sold 1,950 shares, which totaled around $89,700. This transaction was reported in a Form 4 filing with the SEC, sparking interest among investors keen on such activities. Understanding Insider Transactions Insider...
Continue Reading
Cabaletta Bio's Short Interest Surge: What Investors Need to Know
Understanding Cabaletta Bio's Recent Short Interest Trends Cabaletta Bio has seen a noticeable increase in its short percent of float, rising by a significant 38.24% since the previous report. Currently, the company has reported that there are a staggering 6.22 million shares sold short, which represents about 13.16% of all regular shares available for trading. This high...
Continue Reading